Basic Information
| LncRNA/CircRNA Name | BDNF-AS |
| Synonyms | BDNF-AS, ANTI-BDNF, BDNF, BDNF-AS1, BDNFAS, BDNFOS, NCRNA00049 |
| Region | GRCh38_11:27506838-27698174 |
| Ensemble | ENSG00000245573 |
| Refseq | NR_002832 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, in vitro knockdown etc. |
| Sample | prostate cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | BDNF-AS was downregulated in human CaP tumors. Low BDNF-AS expression was correlated with CaP patients' poor prognosis and shorter overall survival. BDNF-AS was also found to be lowly expressed in CaP cell lines. In LNCaP and PC-3 cells, lentivirus-driven BDNF-AS overexpression exerted significantly tumor-suppressing effects on hindering cancer cell proliferation and invasion in vitro, and explant growth in vivo. |
| Pubmed ID | 29710528 |
| Year | 2018 |
| Title | Long noncoding RNA BDNF-AS is associated with clinical outcomes and has functional role in human prostate cancer. |
External Links
| Links for BDNF-AS | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |